Evidence map›Paper›PMID 34287241›Full record

ArticleCurrent oncology (Toronto, Ont.)2021

Clinical Implications of "Atypia" on Biopsy: Possible Precursor to Lung Cancer?

Denise Albano, Lee Ann Santore, Thomas Bilfinger, Melissa Feraca, Samantha Novotny, Barbara Nemesure

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Denise AlbanoLung Cancer Evaluation Center at Stony Brook University Hospital, Stony Brook, NY 11790, USA.
Lee Ann SantoreRenaissance School of Medicine at Stony Brook University, Stony Brook, NY 11790, USA.ORCID 0000-0003-1862-2732
Thomas BilfingerLung Cancer Evaluation Center at Stony Brook University Hospital, Stony Brook, NY 11790, USA.
Melissa FeracaLung Cancer Evaluation Center at Stony Brook University Hospital, Stony Brook, NY 11790, USA.
Samantha NovotnyRenaissance School of Medicine at Stony Brook University, Stony Brook, NY 11790, USA.
Barbara NemesureLung Cancer Evaluation Center at Stony Brook University Hospital, Stony Brook, NY 11790, USA.
Stony Brook University Hospital · USStony Brook School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is common for biopsies of concerning pulmonary nodules to result in cytologic "atypia" on biopsy, which may represent a benign response or a false negative finding. This investigation evaluated time to diagnosis and factors which may predict an ultimate diagnosis of lung cancer in these patients with atypia cytology on lung nodule biopsy.

methodsThis retrospective study included patients of the Stony Brook Lung Cancer Evaluation Center who had a biopsy baseline diagnosis of atypia between 2010 and 2020 and were either diagnosed with cancer or remained disease free by the end of the observation period. Cox Proportional Hazard (CPH) Models were used to assess factor effects on outcomes.

resultsAmong 106 patients with an initial diagnosis of atypia, 80 (75%) were diagnosed with lung cancer. Of those, over three-quarters were diagnosed within 6 months. The CPH models indicated that PET positivity (SUV ≥ 2.5) (HR = 1.74 (1.03, 2.94)), nodule size > 3.5 cm (HR = 2.83, 95% CI (1.47, 5.45)) and the presence of mixed ground glass opacities (HR = 2.15 (1.05, 4.43)) significantly increased risk of lung cancer.

conclusionGiven the high conversion rate to cancer within 6 months, at least tight monitoring, if not repeat biopsy may be warranted during this time period for patients diagnosed with atypia.

Indexed as

Lung NeoplasmsBiopsyHumansLungRetrospective StudiesRisk Factorsatypiacytologylung cancerlung nodulePET

Identifiers

PMID34287241
PMCPMC8293154
OpenAlexW3180118551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.